Intense investigation continues on the pathobiology of stent thrombosis (ST) because of its morbidity and mortality. Because little advance has been made in outcomes following ST, ongoing research is focused on further understanding predictive factors as well as ST frequency and timing in various patient subsets, depending upon whether a drug-eluting stent or bare-metal stent has been implanted. Although the preventive role of antiplatelet therapies remains unchallenged, new data on genomics and variability in response to antiplatelet therapy, as well as the effects of novel therapeutic agents and duration of therapy, have become available. The goal remains identification of patients at particularly increased risk of ST so that optimal prevention strategies can be developed and employed.
|Number of pages||9|
|Journal||Journal of the American College of Cardiology|
|State||Published - Oct 19 2010|
Bibliographical noteFunding Information:
Dr. Kereiakes has received a grant and/or research support from Abbott Vascular , Cordis/Johnson & Johnson , Boston Scientific , and Medtronic ; and consulting fees from Abbott Vascular, Boston Scientific, Cordis/Johnson & Johnson, Devax, and REVA Medical Inc. Dr. Ellis is a consultant for Abbott Vascular, Boston Scientific, and Cordis. Dr. Williams is a consultant for Cordis. Dr. Kimura is an advisory board member for Codis Cardiology and Abbott Vascular. Dr. Moliterno is a consultant for Boston Scientific, Merck/Schering-Plough, Daiichi-Sankyo, and Sanofi-Aventis. All other authors report that they have no relationships to disclose.
- acute myocardial infarction
- bare-metal stent
- drugeluting stent
- dual antiplatelet therapy
- percutaneous coronary intervention
- stent thrombosis
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine